The European Society of Cardiology
Evolution of statin therapy: an ongoing story
University of Aarhus, Aarhus, Denmark
* Ole Faergeman, MD, DMSc, Professor of Preventive Cardiology, Department of Internal Medicine and Cardiology, Faculty of Health Sciences, Aarhus Amtssygehus University Hospital, University of Aarhus, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark. Tel.: +45-8949-7600; fax: +45-8949-7619
ole.faergeman{at}aas.auh.dk
Abstract
Major clinical end-point trials of cholesterol lowering with statins have shown consistent benefits in prevention of cardiovascular disease. Lessons from these trials include the findings that cardiovascular risk reduction is: (1) dependent on baseline cardiovascular risk; (2) dependent on magnitude of low-density lipoprotein cholesterol (LDL-C) reduction achieved with treatment; and (3) independent of initial LDL-C level. Ongoing studies will help to identify new markers of higher risk/higher treatment benefit and to define the merits of more aggressive LDL-C lowering.
Key Words: Statins Cholesterol lowering Cardiovascular disease risk Low-density lipoprotein Coronary heart disease